Core Viewpoint - Fosun Pharma has signed a licensing agreement with Nuco for the development of AR1001, a small molecule oral drug aimed at delaying the progression of Alzheimer's disease [1] Group 1: Company Information - Fosun Pharma's subsidiary, Fosun Pharma Industry, is the entity that entered into the licensing agreement with Nuco [1] - The drug AR1001 is characterized by its potent and highly selective inhibition of phosphodiesterase-5 (PDE-5) [1] Group 2: Product Details - AR1001 is intended for use in delaying the progression of Alzheimer's disease [1] - The drug is licensed from AriBio Co., Ltd., which is the upstream licensor for Nuco [1]

Core Viewpoint - Fosun Pharma has signed a licensing agreement with Newco to develop the AR1001 drug for Alzheimer's disease and other neurological disorders in China and Hong Kong, marking a significant step in the company's expansion into this therapeutic area [1] Group 1: Licensing Agreement Details - Fosun Pharma's subsidiary will pay up to 150 million yuan as an upfront payment and regulatory milestone payments for the rights to develop, register, produce, and commercialize AR1001 in the specified regions [1] - The agreement covers the diagnosis, prevention, and treatment of Alzheimer's disease and other neurological disorders [1] Group 2: Market Context - As of the date of the announcement, there are no approved drugs targeting the same mechanism for treating Alzheimer's disease globally, highlighting the potential market opportunity for AR1001 [1]

Group 1 - Fosun Pharma's stock price increased to 26.66 CNY as of July 25, 2025, reflecting a 1.14% rise from the previous week [1] - The company's market capitalization is currently 71.194 billion CNY, ranking 6th in the chemical pharmaceutical sector and 210th in the A-share market [1] Group 2 - Fosun Pharma announced the establishment of a new subsidiary, Xingrui Jingxuan, with an initial registered capital of 133.5 million CNY, aiming to invest in the nuclear medicine sector [2] - Fosun Pharma will hold approximately 89.89% of the new company, which will focus on integrated diagnostic and therapeutic nuclear medicine products in the oncology field [2] Group 3 - The company completed its A-share and H-share repurchase plans, with a total repurchase amount of approximately 348.36 million CNY for A-shares and 47.84 million HKD for H-shares [3] - The A-share repurchase involved 14,228,552 shares, accounting for 0.5328% of the total share capital, while the H-share repurchase involved 3,410,500 shares, accounting for 0.1277% of the total share capital [3] Group 4 - Fosun Pharma will distribute a cash dividend of 0.32 CNY per share (pre-tax) for the 2024 fiscal year, with a total expected payout of approximately 844.66 million CNY [4] - The ex-dividend date is set for August 4, 2025, with the record date on August 1, 2025 [4] Group 5 - The legal opinion regarding the differentiated profit distribution plan was issued by Guohao Law Firm, confirming the legality of the cash dividend distribution [5] - The company has repurchased a total of 19,906,252 A-shares, which do not have profit distribution rights [5]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (159570) has seen significant inflows and performance, indicating strong investor interest in the innovative drug sector [1][2][5]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) rose nearly 2% today, with a trading volume exceeding 1.3 billion CNY [1]. - As of July 24, the ETF's latest scale surpassed 10.2 billion CNY, leading its peers in the same category [1]. - The ETF's underlying index has shown a 62.78% increase in the first half of 2025, outperforming other medical indices [5][6]. Group 2: Market Dynamics - The ETF has experienced a net inflow of over 230 million CNY in the past four days, reflecting strong market interest [1]. - The financing net purchase amount for the ETF reached 6.2352 million CNY, with the latest financing balance at 206 million CNY [2]. Group 3: Sector Developments - The National Healthcare Security Administration (NHSA) has announced changes to the selection process for medical insurance, moving away from solely considering the lowest bid [3]. - The NHSA's new guidelines are expected to enhance the confidence of companies in R&D investments, particularly in innovative drugs [4]. - The collaboration between dynamic adjustments to the medical insurance catalog and procurement policies is anticipated to shorten the commercialization cycle for innovative drugs [5].

Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced a cash dividend distribution of RMB 0.32 per share (pre-tax) for the fiscal year 2024, approved at the shareholders' meeting on June 24, 2025 [2][4]. Summary by Sections Dividend Distribution Details - The cash dividend of RMB 0.32 per share (pre-tax) will be distributed to all eligible A-share shareholders registered by the close of trading on August 1, 2025 [3][4]. - The total cash dividend distribution is expected to amount to approximately RMB 844.66 million (pre-tax), with A-share shareholders receiving about RMB 671.55 million (pre-tax) [4]. Shareholder Eligibility - Eligible shareholders include all A-share shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the record date [3]. - Shares repurchased and held in a special account will not participate in the distribution [3]. Taxation Information - Individual shareholders holding A-shares will be subject to different tax rates based on their holding period, with a maximum tax rate of 20% for shares held for one month or less [8]. - For qualified foreign institutional investors (QFIIs), a 10% withholding tax will apply, resulting in a net cash dividend of RMB 0.288 per share [10]. - Other investors will receive the full cash dividend of RMB 0.32 per share, with tax obligations to be fulfilled by the shareholders themselves [11]. Implementation Method - The cash dividends will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited, with designated trading investors able to receive their dividends on the payment date [6][11]. - Shanghai Fosun High Technology (Group) Co., Ltd. will receive its cash dividends directly from the company [7].

Group 1 - The core opinion of the document is that the legal opinion confirms the compliance of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. with relevant regulations regarding the differentiated equity distribution plan for 2024 [2][3][6] - The differentiated equity distribution is based on the company's decision to repurchase shares for employee incentive plans and is in accordance with the Shanghai Stock Exchange's guidelines [3][5] - The total cash dividend to be distributed is approximately RMB 671,546,423.36, with a per-share cash dividend of approximately RMB 0.32 [6][7] Group 2 - The repurchased shares, totaling 19,906,252 A shares, do not participate in the profit distribution, which aligns with the regulations set forth by the Shanghai Stock Exchange [5][6] - The calculation of the ex-rights and ex-dividend reference price indicates a minimal impact on the stock price, with the absolute value of the impact being less than 1% [7][8] - The legal opinion emphasizes that the repurchased shares will not affect the distribution of dividends and confirms the legality and accuracy of the distribution plan [2][4][6]

Group 1: Biovaccine ETFs - There are two ETFs named Biovaccine ETF, one managed by Penghua Fund tracking the Guozhen Vaccine and Biotechnology Index, consisting of 50 companies with an average market capitalization of approximately 53.9 billion yuan [1][3] - The second Biovaccine ETF is managed by Harvest Fund, tracking the Zhongzheng Vaccine and Biotechnology Index, which includes up to 50 companies involved in vaccine research and production, with an average market capitalization of about 22 billion yuan [3][5] - The two indices share 19 overlapping constituent stocks, with the Guozhen index having 31 unique stocks and the Zhongzheng index having 24 unique stocks [5][6] - In terms of past performance, the Zhongzheng Vaccine and Biotechnology Index has outperformed the Guozhen index over one, three, and five years, with a notably higher increase in the past year [6][7] Group 2: Biopharmaceutical ETFs - There are two ETFs named Biopharmaceutical ETF, one managed by Tianhong Fund tracking the Guozhen Biopharmaceutical Index, which includes the top 30 companies based on market capitalization and liquidity, with an average market capitalization of around 45.2 billion yuan [11][13] - The second Biopharmaceutical ETF is managed by Guotai Fund, tracking the Zhongzheng Biopharmaceutical Index, which selects companies providing cell therapy, gene sequencing, and other biopharmaceutical services, with an average market capitalization of approximately 71.9 billion yuan [13][15] - The two indices have 18 overlapping constituent stocks, with each index having 12 unique stocks [15][16] - The Zhongzheng Biopharmaceutical Index has consistently outperformed the Guozhen index over one, three, and five years, while the Guozhen index exhibits higher annualized volatility [15][17]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《國浩 律師（上海）事務所關於上海復星醫藥（集團）股份有限公司實施差異化權益分派之法律意見 書》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 致：上海复星医药（集团）股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受上海复星医药（集团） 股份有限公司（以下简称"复星医药"或"公司"）的委托，就公司 2024 年度 实施差异化权益分派（以下简称"本次差异化分派"）事项， ...

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2024 年年度A股權益分派實施公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年7 月2 4 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024年年度A 股权益分派实施公告 证券代码：600196 证券简称：复星医药 公告编号：2025-121 上海复星医药（集团）股份有限公司 重要内容提示： 差异化分红送转： 是 一、通过分配方案的股东会届次和日期 本次利润分配方案已经上海复星医药（集团）股份有限公司（以下简称"本 公司"）2025 年 6 月 24 日召开的2024年度股东会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 每股分配比例 A 股每股现金红利人民币0.32元（税前） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/1 | － | 2025/8/4 | 2025/8/4 | （1）截至股权登记日（即 2025 年 8 月 1 日）下午上海证券交易所收市后， 在中国证券登记结算有限责任公司上海分公司（以下简称"中国结算上海分公司"） ...